The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.
Listed below is the senior management team at BioPharmX.
A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as the aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.
"Our mission at BioPharmX is to fulfill the unmet needs of millions of people whose conditions have been overlooked by others."
Executive Vice President of Finance and Chief Financial Officer
Mr. Kitchener has over 20 years of broad financial leadership experience in financial planning and analysis, treasury, accounting and investor relations. He has a diverse industry background in financial services, high-technology companies such as Cisco Systems and Synopsys, and with the high-growth medical-technology company, Cepheid, where he served as vice president of finance. Kitchener holds a Master of Business Administration from Cornell University and a Bachelor of Science in mathematics from University of California, Santa Cruz.
"Helping the company make prudent financial decisions that deliver sustainable growth, predictable results, and return high shareholder value is the best sense of achievement."
Executive Vice President of Research and Technology
Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, he was Vice President of Engineering at Demira where he helped develop photodynamic therapies, and directed advanced research at Solta Medical where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
"BioPharmX is driven not only by a desire to explore what is possible through scientific breakthroughs but also by what science can do to satisfy the needs of patients."
Senior Advisor of Regulatory and Clinical Affairs
Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology, and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation, and served as an independent consultant for a number of pharmaceutical and medical device companies.
“Being a part of a team that brings new technologies to market that change people’s lives is the most exciting way to start each day.”
Senior Vice President of Corporate Development
A seasoned executive with decades of experience in creating license, distribution and other agreements, Ms. Bots will guide BioPharmX Corporation’s licensing and strategic partnerships. During her three-decade career, she has used licensing, partnerships and strategic acquisitions to boost the sales and profitability at several multinationals. As head of the global skincare business of Royal Philips Electronics NV, she oversaw partnership development and acquisitions, managed joint ventures with companies around the world and launched R&D programs resulting in products sold internationally. Earlier, she managed Philips’ Oral Health Care operations in EMEA leading to growth and profitability. Ms. Bots has also served in executive roles where she built, inspired and managed multi-cultural teams at Aon Risk Solutions, Reed/Elsevier, Beam Suntory, Altadis USA and Royal Agio Cigars. She has a degree in Economics from Fontys University of Applied Sciences in Eindhoven, Netherlands, and she has studied at Erasmus University in Rotterdam and Babson College in Boston.
"The right partnership ad licensing agreements can help BioPharmX achieve its potential by enabling the company to more effectively focus its resources on fulfilling unmet medical needs of patients worldwide."
Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.
"The greatest reward comes from scientific breakthroughs that provide society with therapeutic benefits that have been long hoped-for but always out of reach."